R&D News | pharmaphorum

News

GSK adds to COPD pipeline as Exscientia deal bears fruit

AI drug research firm Exscientia has delivered the first candidate molecule to its partner GlaxoSmithKline following an R&D tie-up signed in 2017.

News

Roche insists Spark deal is still on, despite lacklustre tak...

Shareholders in Spark Therapeutics haven’t been queueing up to take advantage of Roche’s $114.50-per-share offer, forcing an extension to the tender process.

News

AZ's Fasenra also works in rare organ damage diseases

AstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal organ damage, a mid-stage trial has shown.

News

Merck's oral MS drug finally gets FDA okay

Merck KGaA has finally claimed an FDA approval for its oral multiple sclerosis therapy Mavenclad, eight years after being turned down by the US regulator.

News

Novartis buys NASH biotech IFM Tre in potential $1.575 bn de...

Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline.

News

Caucasian male with lack of sleep because he has flu stting in bed and ask for water or medicine. Concept ob being ill alone. Nobody can help him

'Man flu' is real, pharmaphorum research shows

‘Man flu’ is real, according to an exclusive trial carried out by pharmaphorum and based on a new methodology that could revolutionise research into some of the world’s most challenging dis

GSK adds to COPD pipeline as Exscientia deal bears fruit

Roche insists Spark deal is still on, despite lacklustre tak...

AZ's Fasenra also works in rare organ damage diseases

Merck's oral MS drug finally gets FDA okay

Novartis buys NASH biotech IFM Tre in potential $1.575 bn de...

'Man flu' is real, pharmaphorum research shows

Electra sets terms for IPO, hoping to raise up to $347m

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks